199 related articles for article (PubMed ID: 26990772)
21. Interaction with PALB2 Is Essential for Maintenance of Genomic Integrity by BRCA2.
Hartford SA; Chittela R; Ding X; Vyas A; Martin B; Burkett S; Haines DC; Southon E; Tessarollo L; Sharan SK
PLoS Genet; 2016 Aug; 12(8):e1006236. PubMed ID: 27490902
[TBL] [Abstract][Full Text] [Related]
22. Prevalence of PALB2 mutations in Australasian multiple-case breast cancer families.
Teo ZL; Park DJ; Provenzano E; Chatfield CA; Odefrey FA; Nguyen-Dumont T; ; Dowty JG; Hopper JL; Winship I; Goldgar DE; Southey MC
Breast Cancer Res; 2013 Feb; 15(1):R17. PubMed ID: 23448497
[TBL] [Abstract][Full Text] [Related]
23. Genotype-cancer association in patients with Fanconi anemia due to pathogenic variants in FANCD1 (BRCA2) or FANCN (PALB2).
McReynolds LJ; Biswas K; Giri N; Sharan SK; Alter BP
Cancer Genet; 2021 Nov; 258-259():101-109. PubMed ID: 34687993
[TBL] [Abstract][Full Text] [Related]
24. PALB2 regulates recombinational repair through chromatin association and oligomerization.
Sy SM; Huen MS; Zhu Y; Chen J
J Biol Chem; 2009 Jul; 284(27):18302-10. PubMed ID: 19423707
[TBL] [Abstract][Full Text] [Related]
25. Gene of the month: PALB2.
Hamdan O; Nowak KM
J Clin Pathol; 2023 Feb; 76(2):73-75. PubMed ID: 36600573
[TBL] [Abstract][Full Text] [Related]
26. PALB2 analysis in BRCA2-like families.
Adank MA; van Mil SE; Gille JJ; Waisfisz Q; Meijers-Heijboer H
Breast Cancer Res Treat; 2011 Jun; 127(2):357-62. PubMed ID: 20582465
[TBL] [Abstract][Full Text] [Related]
27. PALB2: the hub of a network of tumor suppressors involved in DNA damage responses.
Park JY; Zhang F; Andreassen PR
Biochim Biophys Acta; 2014 Aug; 1846(1):263-75. PubMed ID: 24998779
[TBL] [Abstract][Full Text] [Related]
28. RAD52 inactivation is synthetically lethal with deficiencies in BRCA1 and PALB2 in addition to BRCA2 through RAD51-mediated homologous recombination.
Lok BH; Carley AC; Tchang B; Powell SN
Oncogene; 2013 Jul; 32(30):3552-8. PubMed ID: 22964643
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of the need for routine clinical testing of PALB2 c.1592delT mutation in BRCA negative Northern Finnish breast cancer families.
Haanpää M; Pylkäs K; Moilanen JS; Winqvist R
BMC Med Genet; 2013 Aug; 14():82. PubMed ID: 23941127
[TBL] [Abstract][Full Text] [Related]
30. Recruitment of fanconi anemia and breast cancer proteins to DNA damage sites is differentially governed by replication.
Shen X; Do H; Li Y; Chung WH; Tomasz M; de Winter JP; Xia B; Elledge SJ; Wang W; Li L
Mol Cell; 2009 Sep; 35(5):716-23. PubMed ID: 19748364
[TBL] [Abstract][Full Text] [Related]
31. Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins.
Wang W
Nat Rev Genet; 2007 Oct; 8(10):735-48. PubMed ID: 17768402
[TBL] [Abstract][Full Text] [Related]
32. The two faces of BRCA2, a FANCtastic discovery.
Stewart G; Elledge SJ
Mol Cell; 2002 Jul; 10(1):2-4. PubMed ID: 12150898
[TBL] [Abstract][Full Text] [Related]
33. [Fanconi anemia--genotoxic stress and senescence of hematopoietic stem cells].
Yamashita T; Oda T; Sekimoto T
Nihon Rinsho; 2008 Mar; 66(3):477-82. PubMed ID: 18330024
[TBL] [Abstract][Full Text] [Related]
34. Analysis of PALB2 gene in BRCA1/BRCA2 negative Spanish hereditary breast/ovarian cancer families with pancreatic cancer cases.
Blanco A; de la Hoya M; Osorio A; Diez O; Miramar MD; Infante M; Martinez-Bouzas C; Torres A; Lasa A; Llort G; Brunet J; Graña B; Perez Segura P; Garcia MJ; Gutiérrez-Enríquez S; Carracedo Á; Tejada MI; Velasco EA; Calvo MT; Balmaña J; Benitez J; Caldés T; Vega A
PLoS One; 2013; 8(7):e67538. PubMed ID: 23935836
[TBL] [Abstract][Full Text] [Related]
35. Fanconi anemia: causes and consequences of genetic instability.
Kalb R; Neveling K; Nanda I; Schindler D; Hoehn H
Genome Dyn; 2006; 1():218-242. PubMed ID: 18724063
[TBL] [Abstract][Full Text] [Related]
36. PALB2 is an integral component of the BRCA complex required for homologous recombination repair.
Sy SM; Huen MS; Chen J
Proc Natl Acad Sci U S A; 2009 Apr; 106(17):7155-60. PubMed ID: 19369211
[TBL] [Abstract][Full Text] [Related]
37. A genetic screen identifies BRCA2 and PALB2 as key regulators of G2 checkpoint maintenance.
Menzel T; Nähse-Kumpf V; Kousholt AN; Klein DK; Lund-Andersen C; Lees M; Johansen JV; Syljuåsen RG; Sørensen CS
EMBO Rep; 2011 Jul; 12(7):705-12. PubMed ID: 21637299
[TBL] [Abstract][Full Text] [Related]
38. Heterozygous mutations in the PALB2 hereditary breast cancer predisposition gene impact on the three-dimensional nuclear organization of patient-derived cell lines.
Wark L; Novak D; Sabbaghian N; Amrein L; Jangamreddy JR; Cheang M; Pouchet C; Aloyz R; Foulkes WD; Mai S; Tischkowitz M
Genes Chromosomes Cancer; 2013 May; 52(5):480-94. PubMed ID: 23341105
[TBL] [Abstract][Full Text] [Related]
39. Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer.
Casadei S; Norquist BM; Walsh T; Stray S; Mandell JB; Lee MK; Stamatoyannopoulos JA; King MC
Cancer Res; 2011 Mar; 71(6):2222-9. PubMed ID: 21285249
[TBL] [Abstract][Full Text] [Related]
40. Assessment of PALB2 as a candidate melanoma susceptibility gene.
Aoude LG; Xu M; Zhao ZZ; Kovacs M; Palmer JM; Johansson P; Symmons J; Trent JM; Martin NG; Montgomery GW; Brown KM; Hayward NK
PLoS One; 2014; 9(6):e100683. PubMed ID: 24949998
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]